Stock Events

Royalty Pharma 

$31.03
215
+$0.01+0.03% Friday 21:00

Statistics

Day High
31.22
Day Low
30.75
52W High
36.62
52W Low
25.17
Volume
2,378,928
Avg. Volume
3,271,536
Mkt Cap
13.86B
P/E Ratio
16.51
Dividend Yield
2.71%
Dividend
0.84

Upcoming

Dividends

2.71%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
7.3%
1Y Growth
5%

Earnings

7MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
0.72
1.01
1.31
1.6
Expected EPS
0.86
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RPRX. It's not an investment recommendation.

Analyst Ratings

49.67$Average Price Target
The highest estimate is $57.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. The company has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. Royalty Pharma plc was founded in 1996 and is based in New York, New York.
Show more...
CEO
Country
GB
ISIN
GB00BMVP7Y09
WKN
000A2P62D

Listings